COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 28, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

December 30, 2021

Conditions
COVID-19 Pneumonia
Interventions
BIOLOGICAL

Bacillus subtilis

Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.

Trial Locations (2)

98125

DreamTec Research Limited, Hong Kong

Unknown

Middle East Cell and Gene Therapy, Tehran

All Listed Sponsors
collaborator

Middle East Cell and Gene Therapy

UNKNOWN

collaborator

National Institute of Genetic Engineering and Biotechnology

UNKNOWN

lead

DreamTec Research Limited

INDUSTRY

NCT05239923 - COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores | Biotech Hunter | Biotech Hunter